[News Space=Reporter seungwon lee] Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, hosted the ‘Korea–China Medical Aesthetics Exchange Forum’ in Seoul on Tuesday to strengthen academic collaboration between medical professionals from the two countries.

The event aimed to share Korea’s latest aesthetic treatment techniques and clinic management expertise, while enhancing understanding of Chinese patients visiting Korea. Attendees included representatives from Hugel’s Chinese partner Sihuan Pharmaceutical, leading healthcare professionals from both countries, Hugel Vice President Seanguk Ji and members of the company’s Chinese unit and domestic sales division.

The forum featured discussions on key topics such as aesthetic trends for 2026, next-generation anti-aging strategies, and clinic operation models, while assessing the current landscape of the Korean and Chinese markets. Directors from Daybeau Clinic’s Myeongdong and Gangnam branches shared practical insights from their clinical experience. Jeonghwan Kim, Director of Dr. Evers Clinic Myeongdong, delivered a lecture and live demonstration on combination treatments using botulinum toxin and hyaluronic acid dermal fillers.

Through the program, Chinese medical professionals experienced the precision of Korean aesthetic techniques and reviewed clinical cases, while gaining insights into the various applications of Hugel’s botulinum toxin Letybo. Korean practitioners gained a deeper understanding of the needs of Chinese patients.

“Since entering the Chinese market, Hugel has strengthened the Letybo brand and built trust based on three key pillars: authenticity, academic excellence, and premium product positioning,” Hugel’s Vice President Ji said. “We will continue to create platforms for exchange between Korean and Chinese medical professionals and foster collaboration through the exchange of knowledge and clinical experience,” he added.